Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30590049 | 1.00 | ADORA1 (0.41) | ADORA1ALDH1A1HSD17B10LMNANOS1 | |
| SCHEMBL9412613 | 0.85 | JAK3 (0.32) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL5483576 | 0.84 | ADORA1 (0.40) | ADORA1ALDH1A1HSD17B10LMNANOS1 | |
| SCHEMBL29665061 | 0.84 | ADORA1 (0.40) | ADORA1ALDH1A1HSD17B10LMNANOS1 | |
| SCHEMBL887124 | 0.83 | CYP1A2 (0.40) | ADORA1ALDH1A1LMNARAB9AKDM4E | |
| SCHEMBL21050252 | 0.80 | PRKD3 (0.42) | ADORA1ALDH1A1HSD17B10LMNANOS1 | |
| SCHEMBL4777463 | 0.78 | GDA (0.42) | ADORA1ALDH1A1HSD17B10LMNANOS1 | |
| SCHEMBL9412566 | 0.78 | KDM4E (0.35) | ALDH1A1LMNANPC1RAB9AKDM4E | |
| SCHEMBL9412633 | 0.77 | ALDH1A1 (0.35) | ALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL377762 | 0.76 | PDPK1 (0.33) | LMNACDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7314923-B2 | Nucleoside and oligonucleotide analogues | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-01-01 | — | — | US | claimed |
| US-20260035403-A1 | NUCLEOSIDE LINE-1 INHIBITORS | TRANSPOSON THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250215039-A1 | NUCLEOSIDES FOR TREATING CANCER | PRIMEFOUR THERAPEUTICS INC (US) | 2025-07-03 | — | — | US | disclosed |
| EP-4499106-A2 | NUCLEOSIDE LINE-1 INHIBITORS | Transposon Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-118146285-A | Modified nucleoside, preparation method thereof, oligonucleotide prepared from modified nucleoside and application of oligonucleotide | 北京悦康科创医药科技股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2023192499-A1 | NUCLEOSIDES FOR TREATING CANCER | PRIMEFOUR THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192491-A2 | NUCLEOSIDE LINE-1 INHIBITORS | TRANSPOSON THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-11213592-B2 | Antibody-sting agonist conjugates and their use in immunotherapy | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210290774-A1 | ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | US | disclosed |
| US-11033635-B2 | Antibody-STING agonist conjugates and their use in immunotherapy | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210015941-A1 | ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11213592-B2 | Antibody-sting agonist conjugates and their use in immunotherapy | STING1, CGAS, MAVS | ADORA1 378/4885ALDH1A1 4589/4885HSD17B10 4748/4885 |
| US-20210290774-A1 | ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY | STING1, CGAS, MAVS | ADORA1 378/4885ALDH1A1 4589/4885HSD17B10 4748/4885 |
| US-20260035403-A1 | NUCLEOSIDE LINE-1 INHIBITORS | L3MBTL1, TDP1, TRDMT1 | ADORA1 652/4885ALDH1A1 1904/4885HSD17B10 3176/4885 |
| US-11033635-B2 | Antibody-STING agonist conjugates and their use in immunotherapy | STING1, CGAS, MAVS | ADORA1 378/4885ALDH1A1 4589/4885HSD17B10 4748/4885 |
| US-20250215039-A1 | NUCLEOSIDES FOR TREATING CANCER | UNG, OGG1, NTPCR | ADORA1 427/4885ALDH1A1 635/4885HSD17B10 1666/4885 |
| US-20210015941-A1 | ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY | STING1, CGAS, MAVS | ADORA1 378/4885ALDH1A1 4589/4885HSD17B10 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.